DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB

直接管理/腺病毒载体 W/VEGF121/ CDNA 至下肢缺血

• 批准号: 6304094
• 负责人: RONALD G CRYSTAL
• 金额: $ 7.95万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6304094
• 关键词: Adenoviridae; blood disorder chemotherapy; blood vessel occlusion; blood vessels; clinical research; clinical trials; drug administration routes; gene therapy; human subject; human therapy evaluation; ischemia; limbs; transfection /expression vector; vascular endothelial growth factors

This protocol is designed to determine the safety/toxicity and biologic efficacy of direct administration of the AdGVVEGF121.10 vector to the lower limb of individuals with peripheral vascular disease. At the conclusion of the study, in addition to the objective described above, the investigators will demonstrate whether direct administration of AdGVVEGF121.10 to the lower limb will induce growth of collateral blood vessels, improve blood flow in the region of ischemia.

该方案旨在确定将AdGVVEGF 121.10载体直接施用至患有外周血管疾病的个体的下肢的安全性/毒性和生物学功效。在研究结束时，除了上述目的外，研究者将证明直接给予下肢AdGVVEGF 121.10是否会诱导侧支血管的生长，改善缺血区域的血流。